Bokhman's dualistic model of endometrial carcinoma. Revisited.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Gynecologic oncology · 2016
   Trial
2. Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer.Frontiers in oncology · 2024
   Review
3. Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.Frontiers in oncology · 2022
   Article
4. A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening.Laboratory investigation; a journal of technical methods and pathology · 2021
   Article
5. PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer.Oncogene · 2021
   Article
6. Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma.Journal of clinical medicine · 2021
   Review
7. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2020
   Review
8. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.BMC cancer · 2018
   Article
9. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.PloS one · 2018
   Article

Corrections and comments

• Comment on
  Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.2013

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as